SCHEMBL4387319

SCHEMBL4387319

CCCCc1ccc(S(=O)(=O)N2CCC(=NOCc3ccc(Cl)cc3)CC2)cc1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.47
GAA P10253 2/20 0.47
MAPT P10636 2/20 0.47
CYP2C19 P33261 2/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2C9 P11712 1/20 0.47
SMN1; SMN2 Q16637 5/20 0.46
LMNA P02545 4/20 0.46
PKM P14618 2/20 0.46
HTT P42858 1/20 0.46
KMT2A Q03164 2/20 0.45
TDP1 Q9NUW8 1/20 0.45
POLB P06746 2/20 0.44
MAPK1 P28482 1/20 0.44
MEN1 O00255 1/20 0.43
FAAH O00519 1/20 0.43
MGLL Q99685 1/20 0.43
ATM Q13315 1/20 0.42
LSS P48449 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4393905 0.90 SMN1; SMN2 (0.49) ALDH1A1GAACYP2C19CYP2C9SMN1; SMN2
SCHEMBL4376967 0.90 ALDH1A1 (0.56) ALDH1A1GAAMAPTCYP2C19CYP3A4
SCHEMBL4385481 0.90 LMNA (0.49) ALDH1A1GAAMAPTSMN1; SMN2LMNA
SCHEMBL4381821 0.88 LMNA (0.46) ALDH1A1SMN1; SMN2LMNAHTTKMT2A
SCHEMBL4376971 0.88 SMN1; SMN2 (0.40) ALDH1A1GAACYP2C19CYP3A4CYP2C9
SCHEMBL4383812 0.87 LMNA (0.48) ALDH1A1GAAMAPTCYP2C19SMN1; SMN2
SCHEMBL4395422 0.86 SMN1; SMN2 (0.39) ALDH1A1GAAMAPTSMN1; SMN2LMNA
SCHEMBL4385187 0.85 IKBKB (0.42) SMN1; SMN2LMNAKMT2AMAPK1MEN1
SCHEMBL4393979 0.85 IKBKB (0.41) ALDH1A1GAAMAPTSMN1; SMN2LMNA
SCHEMBL4380726 0.84 ALDH1A1 (0.51) ALDH1A1GAAMAPTCYP2C19CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090298878-A1 OXIME COMPOUNDS AND THE USE THEREOF PURDUE PHARMA L.P. 2009-12-03 US disclosed
US-20090298878-A1 OXIME COMPOUNDS AND THE USE THEREOF PURDUE PHARMA L.P. 2009-12-03 US disclosed
US-20090298878-A1 OXIME COMPOUNDS AND THE USE THEREOF PURDUE PHARMA L.P. 2009-12-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090298878-A1 OXIME COMPOUNDS AND THE USE THEREOF KCNN4, CACNA1A, KCNN3 ALDH1A1 2105/4885GAA 3245/4885MAPT 4378/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.